These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 9363230

  • 21. Higher median levels of free beta-hCG and PAPP-A in the first trimester of pregnancy in a Chinese ethnic group. Implication for first trimester combined screening for Down's syndrome in the Chinese population.
    Leung TY, Spencer K, Leung TN, Fung TY, Lau TK.
    Fetal Diagn Ther; 2006; 21(1):140-3. PubMed ID: 16354992
    [Abstract] [Full Text] [Related]

  • 22. Maternal serum free beta-hCG and PAPP-A in patients with habitual abortion-influence on first-trimester screening for chromosomal abnormalities.
    Heinig J, Steinhard J, Schmitz R, Nofer JR, Kiesel L, Klockenbusch W.
    Prenat Diagn; 2007 Sep; 27(9):814-6. PubMed ID: 17554803
    [Abstract] [Full Text] [Related]

  • 23. First trimester Down's syndrome screening marker values and cigarette smoking: new data and a meta-analysis on free beta human chorionic gonadotophin, pregnancy-associated plasma protein-A and nuchal translucency.
    Bestwick JP, Huttly WJ, Wald NJ.
    J Med Screen; 2008 Sep; 15(4):204-6. PubMed ID: 19106261
    [Abstract] [Full Text] [Related]

  • 24. Screening for Down's syndrome--too many choices?
    Mennuti MT, Driscoll DA.
    N Engl J Med; 2003 Oct 09; 349(15):1471-3. PubMed ID: 14534341
    [No Abstract] [Full Text] [Related]

  • 25. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy.
    Odibo A.
    Br J Obstet Gynaecol; 1996 Nov 09; 103(11):1173-4. PubMed ID: 8917014
    [No Abstract] [Full Text] [Related]

  • 26. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes.
    Barrett SL, Bower C, Hadlow NC.
    Prenat Diagn; 2008 Jan 09; 28(1):28-35. PubMed ID: 18186146
    [Abstract] [Full Text] [Related]

  • 27. First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome.
    Wald N, Stone R, Cuckle HS, Grudzinskas JG, Barkai G, Brambati B, Teisner B, Fuhrmann W.
    BMJ; 1992 Jul 04; 305(6844):28. PubMed ID: 1379094
    [No Abstract] [Full Text] [Related]

  • 28. [Prenatal diagnostics during the first trimester in the clinical praxis].
    Calda P, Vísková H, Bezdícková D, Zima T.
    Cas Lek Cesk; 2006 Jul 04; 145(7):575-7. PubMed ID: 16921789
    [Abstract] [Full Text] [Related]

  • 29. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
    Wald NJ, Watt HC, Hackshaw AK.
    N Engl J Med; 1999 Aug 12; 341(7):461-7. PubMed ID: 10441601
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland.
    Niemimaa M, Suonpää M, Perheentupa A, Seppälä M, Heinonen S, Laitinen P, Ruokonen A, Ryynänen M.
    Eur J Hum Genet; 2001 Jun 12; 9(6):404-8. PubMed ID: 11436120
    [Abstract] [Full Text] [Related]

  • 31. Response to: Wald, N.J., Hackshaw, A.K. (1997). Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome, Prenat. Diagn., 17, 821-829.
    Reynolds TM, Dunstan F, Nix B, Williams K, Crossley J, Holding S, Krantz D, Wright D, Bray I, Spencer K.
    Prenat Diagn; 1998 May 12; 18(5):511-9. PubMed ID: 9621388
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Repeated measures screening for Down's Syndrome.
    Wright DE, Bradbury I.
    BJOG; 2005 Jan 12; 112(1):80-3. PubMed ID: 15663402
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Immunoassay-Amplified Responses Using a Functionalized MoS2-Based SPR Biosensor to Detect PAPP-A2 in Maternal Serum Samples to Screen for Fetal Down's Syndrome.
    Chiu NF, Tai MJ, Nurrohman DT, Lin TL, Wang YH, Chen CY.
    Int J Nanomedicine; 2021 Jan 12; 16():2715-2733. PubMed ID: 33859474
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.